Health ❯ Healthcare ❯ Pharmacology

Targeted Therapy

Epidermal Growth Factor Receptor Inhibitors RET Inhibitors Taletrectinib Camizestrant RAS Inhibitors HER2 Inhibitors Lenvatinib and Everolimus PARP Inhibitors Tucatinib Pan-RAF Inhibitors BRAF Inhibitors HER2-Targeted Agents TROP-2 Dual-Pathway Inhibition T-DXd (Enhertu) Tyrosine Kinase Inhibitors (TKIs)

Selpercatinib Dramatically Cuts Recurrence in Early-Stage RET-Positive Lung Cancer

An interim phase III analysis raises the prospect of a new adjuvant standard as overall survival and longer follow-up remain pending.

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

HER2 Drug Trio Extends Survival in Phase II Study of Breast Cancer Leptomeningeal Metastasis